4 completed, 1 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
Follow Amifampridine Phosphate: new trials by email Literature Review of Amifampridine Phosphate trials Research Report on Amifampridine Phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Amifampridine Phosphate - Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | Phase 3 | Terminated | Catalyst Pharmaceuticals, Inc. | 63 | 2018-06-11 | 2024-05-07 |
| Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Amifampridine Phosphate, Placebo Oral Tablet - Myasthenia Gravis, Generalized | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 93 | 2018-04-18 | 2024-03-12 |
| Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Amifampridine Phosphate, Placebo Oral Tablet - Lambert-Eaton Myasthenic Syndrome | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 26 | 2016-11-01 | 2018-12-24 |
| Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes amifampridine phosphate, Placebo - Myasthenic Syndromes, Congenital | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 20 | 2016-01-01 | 2021-04-02 |
| A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Amifampridine Phosphate, Placebo - Lambert Eaton Myasthenic Syndrome | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 38 | 2011-06-01 | 2018-01-04 |
Lambert-Eaton Myasthenic Syndrome (2) · Myasthenia Gravis (2) · Myasthenic Syndromes, Congenital (1)
Catalyst Pharmaceuticals, Inc. (5)
United States (5) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Russia (1) · Serbia (1) · Spain (1)
Renato Mantegazza, MD (2) · Charles W Gorodetzky, MD, PhD (1) · Perry Shieh, MD, PhD (1) · Thomas Crawford, M.D. (1)